CD44 and breast carcinoma: The proportion of CD44+/CD24−/low after chemotherapy therapy was 9.5 times higher than that before chemotherapy in breast cancer, and breast CSCs served as an independent risk factor for predicting poor survival in breast cancer patients (Tanei et al., 2009).